Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Pharma Bureau Eyes 12 Billion Yen to Boost Plasma Product Production
The Ministry of Health, Labor and Welfare’s (MHLW) Pharmaceutical Safety Bureau has requested 33.49 billion yen for FY2027, more than triple its FY2026 budget, driven by a series of large new requests under the government’s investment framework for crisis preparedness…
To read the full story
Related Article
- Japan Moves to Break Plasma Product Capacity Crunch with Factory Aid
October 6, 2026
- KM Biologics Eyes Plasma Product Capacity Expansion with Govt Backing
September 30, 2026
- New MHLW Pharma Chief Puts AI in Regulatory Reviews High on Agenda
September 3, 2026
- MHLW Seeks Record 36.6 Trillion Yen for FY2027, Puts AI in Focus
August 27, 2026
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- Japan’s Immunoglobulin Self-Sufficiency Rate Falls Below 60%
June 29, 2026
REGULATORY
- SCARDA, Thai Vaccine Institute Link Up on KM Biologics’ Dengue Shot
October 7, 2026
- MHLW Opens Applications for Innovation Fund’s Ecosystem Program
October 7, 2026
- Takaichi Puts Health Security on Crisis Management Investment Agenda
October 6, 2026
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- RMPs to Become Statutory Requirement under PMD Act in May 2027
October 5, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…